Activation of STAT1 promotes T-cell recruitment, NASH, and fibrosis, but not HCC, whereas inhibition of STAT3 signaling prevented HCC without affecting NASH and fibrosis,427 suggesting the possibility of separative treatment of NASH and HCC. Here, STAT1 is linked to metabolic dysfunction-associated steatohepatitis.